A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma Meeting Abstract
| Authors: | Langenberg, M. H.; Gluck, L.; Weger, V.; Frank, R.; Eskens, F.; Blay, J. Y.; Soria, J. C.; Chawla, S.; Gounder, M.; Wagner, A.; Zhang, Y.; Kambuj, P.; Loberg, R.; Henary, H. |
| Abstract Title: | A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma |
| Meeting Title: | 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 69 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Nov 29-Dec 2 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2016-12-01 |
| Start Page: | S34 |
| Language: | English |
| ACCESSION: | WOS:000390503500077 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(16)32682-X |
| Notes: | Meeting Abstract: 82 -- 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 29-DEC 02, 2016 -- Munich, GERMANY -- Source: Wos |
